News
3h
Zacks Investment Research on MSNHere's What Key Metrics Tell Us About Moderna (MRNA) Q2 EarningsFor the quarter ended June 2025, Moderna (MRNA) reported revenue of $142 million, down 41.1% over the same period last year. EPS came in at -$2.13, compared to -$3.33 in the year-ago quarter. The ...
Live Updates Live Coverage Updates appear automatically as they are published. Moderna Still Sickly 9:49 am In further ...
CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its ...
Moderna reduced its 2025 revenue forecast due to deferred UK vaccine deliveries. Despite a smaller-than-expected quarterly loss, its shares fell 7%. The company faces challenges from declining ...
Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss ...
7h
Zacks Investment Research on MSNMRNA Beats on Q2 Earnings & Sales, Stock Down on Lowered Sales ViewModerna MRNA incurred a loss of $2.13 per share in the second quarter of 2025, narrower than the Zacks Consensus Estimate of ...
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...
Circular RNA may be part of the solution. Because circular RNA has no ends to degrade—unlike linear RNA—the molecule is more stable and its half-life is extended.
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...
A U.K. Court of Appeals ruling confirms the validity of a patent covering modifications of mRNA used in Moderna’s vaccines.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results